Ophthalmology ReportsOphthalmology ReportsОфтальмологические ведомости1998-71022412-5423Eco-Vector6285710.17816/OV62857Original study articlesОригинальные исследованияResearch ArticleThe platelet-rich plasma lysate use in the treatment of persistent epithelial defects after keratoplastyПрименение лизата обогащенной тромбоцитами плазмы в лечении пациентов с персистирующими эпителиальными дефектами после кератопластикиhttps://orcid.org/0000-0002-1857-6425ShakhbazyanNare P.ШахбазянНаре Петросовна
Russian Federation

postgraduate student

аспирантка

nare_shakhbazyan@mail.ruhttps://orcid.org/0000-0003-4360-793XTrufanovSergey V.ТруфановСергей Владимирович
Russian Federation

MD, Dr. Sci. (Med.)

д-р мед. наук

trufanov05@mail.ruhttps://orcid.org/0000-0002-8258-6011SubbotAnastasia M.СубботАнастасия Михайловна
Russian Federation

PhD, Cand. Sci. (Med.)

канд. мед. наук

kletkagb@gmail.comResearch Institute of Eye DiseasesНаучно-исследовательский институт глазных болезнейPavlov First St. Petersburg State Medical UniversityПервый Санкт-Петербургский государственный медицинский университет им. академика И.П. Павлова3009202114227351803202129062021Copyright ©; 2021, Shakhbazyan N.P., Trufanov S.V., Subbot A.M.Copyright ©; 2021, Шахбазян Н.П., Труфанов С.В., Суббот А.М.Copyright ©; 2021, Shakhbazyan N., Trufanov S., Subbot A.2021Shakhbazyan N.P., Trufanov S.V., Subbot A.M.Шахбазян Н.П., Труфанов С.В., Суббот А.М.Shakhbazyan N., Trufanov S., Subbot A.http://creativecommons.org/licenses/by/4.0https://journals.eco-vector.com/ov/article/view/62857

AIM: to evaluate the effectiveness of the platelet-rich plasma lysate (PRP lysate) use in the treatment of persistent epithelial defects (PED) after keratoplasty.

MATERIALS AND METHODS: In the study, 60 patients with PED after keratoplasty were included. The 1st group (24 cases) included patients after keratoplasty with “low risk” of rejection, and the 2nd group – 36 cases after keratoplasty with “high risk” of rejection. Each group was divided into two subgroups – control subgroups 1a (cases 10) and 2a (cases 16), where patients received only standard postoperative therapy, and the main subgroups 1b (cases 14) and 2b (cases 20), in which PRP lysate was prescribed against the background of standard therapy, starting from the Day 15 post-op. As the criterion for effective treatment, complete persistent epithelialization after keratoplasty was considered.

RESULTS: The effectiveness of the use of PRP lysate in the subgroup 1b was 85.7%, while complete epithelialization in the control subgroup 1a was recorded in 70%; in the subgroup 2b, complete epithelialization was observed in 55%, in the control subgroup 2a – in 43.75%.

CONCLUSION: The use of PRP lysate in the treatment of PED after corneal transplantation as an adjuvant therapy is effective and safe in both high and low risk keratoplasty. In the examined category of patients, treatment with blood derivatives increases the frequency and rate of complete epithelialization.

Цель исследования. Оценить эффективность применения лизата обогащенной тромбоцитами плазмы (лизат ОбТП) в лечении пациентов с персистирующими эпителиальными дефектами (ПЭД) после кератопластики.

Материалы и методы. В исследование было включено 60 пациентов с ПЭД после кератопластики: 1-я группа (n = 24) включала больных после кератопластики «низкого риска»; 2-я группа (n = 36) — после кератопластики «высокого риска» отторжения. Каждая группа была разделена на две подгруппы — контрольные 1а (n = 10) и 2а (n = 16), где пациенты получали только стандартную послеоперационную терапию, и основные 1б (n = 14) и 2б (n = 20), где на фоне стандартной терапии начиная с 15-х послеоперационных суток назначали инстилляции глазных капель лизата ОбТП. Критерием эффективного лечения считали полную стойкую эпителизацию после кератопластики.

Результаты исследования. Эффективность применения лизата ОбТП в подгруппе 1б составила 85,7 %, тогда как полная эпителизация в контрольной подгруппе 1а зафиксирована в 70 %; в подгруппе 2б полная эпителизация наблюдалась в 55 %, в контрольной подгруппе 2а — 43,75 %.

Заключение. Применение глазных капель лизата ОбТП в лечении при ПЭД после трансплантации роговицы в качестве адъювантной терапии эффективно и безопасно при кератопластике как высокого, так и низкого риска. У обследуемой категории больных лечение дериватами крови увеличивает частоту и скорость полной эпителизации.

epithelial defectplatelet-rich plasma lysatekeratoplastycorneal epitheliumэпителиальный дефектлизат обогащенной тромбоцитами плазмыкератопластикаLynch MD, Bashir S. Applications of platelet-rich plasma in dermatology: A critical appraisal of the literature. Journal of Dermatological Treatment. 2016;27(3):285–289. DOI: 10.3109/09546634.2015.1094178Lynch M.D., Bashir S. Applications of platelet-rich plasma in dermatology: A critical appraisal of the literature // Journal of Dermatological Treatment. 2016. Vol. 27, No. 3. P. 285–289. DOI: 10.3109/09546634.2015.1094178Andia E, Rubio-Azpeitia J, Martin JI, Abate M. Current concepts and translational uses of platelet rich plasma biotechno-logy. Biotechnology, Deniz Ekinci, IntechOpen. 2015. DOI: 10.5772/59954Andia E., Rubio-Azpeitia J., Martin J.I., Abate M. Current concepts and translational uses of platelet rich plasma biotechnology. Biotechnology, Deniz Ekinci, IntechOpen. 2015. DOI: 10.5772/59954.Sommeling CE, Heyneman A, Hoeksema H, et al. The use of platelet-rich plasma in plastic surgery: a systematic review. J Plast Reconstr Aesthet Surg. 2013;66(3):301–311. DOI: 10.1016/j.bjps.2012.11.009Sommeling C.E., Heyneman A., Hoeksema H., et al. The use of platelet-rich plasma in plastic surgery: a systematic review // J Plast Reconstr Aesthet Surg. 2013. Vol. 66, No. 3. P. 301–311. DOI: 10.1016/j.bjps.2012.11.009Mazzucco L, Balbo V, Cattana E, et al. Not every PRP-gel is born equal. Evaluation of growth factor availability for tissues through four PRP-gel preparations: Fibrinet, Regen PRP-kit, Plateltex and one manual procedure. Vox Sang. 2009;97(2):110–118. DOI: 10.1111/j.1423-0410.2009.01188. xMazzucco L., Balbo V., Cattana E., et al. Not every PRP-gel is born equal. Evaluation of growth factor availability for tissues through four PRP-gel preparations: Fibrinet, Regen PRP-kit, Plateltex and one manual procedure // Vox Sang. 2009. Vol. 97, No. 2. P. 110–118. DOI: 10.1111/j.1423–0410.2009.01188.xLe G, Kaux JF, Seidel L, et al. Étude comparative de cinq techniques de préparation plaquettaire (platelet-rich plasma). Pathol Biol. (Paris). 2011;59(3):157–160. (In French.) DOI: 10.1016/j.patbio.2009.04.007Le G., Kaux J.F., Seidel L., et al. Étude comparative de cinq techniques de préparation plaquettaire (platelet-rich plasma) // Pathol Biol. 2011;59:157–160. DOI: 10.1016/j.patbio.2009.04.007Castillo TN, Pouliot MA, Kim HJ, Dragoo JL. Comparison of growth factor and platelet concentration from commercial platelet-rich plasma separation systems. Am J Sports Med. 2010;39(2): 266–271. DOI: 10.1177/0363546510387517Castillo T.N., Pouliot M.A., Kim H.J., Dragoo J.L. Comparison of growth factor and platelet concentration from commercial platelet-rich plasma separation system // Am J Sports Med. 2010. Vol. 39, No. 2. P. 266–271. DOI: 10.1177/0363546510387517Wasterlain AS, Braun HJ, Dragoo JL. Contents and formulations of platelet rich plasma. Platelet Rich Plasma in Musculoskeletal Practice. London; 2016. P. 1–29.Wasterlain A.S., Braun H.J., Dragoo J.L. Contents and formulations of platelet rich plasma. Platelet Rich Plasma in Musculoskeletal Practice. London. 2016. P. 1–29.Bieback K. Platelet lysate as replacement for fetal bovine serum in mesenchymal stromal cell cultures. Transfus Med Hemother. 2013;40(5):326–335. DOI: 10.1159/000354061Bieback K. Platelet lysate as replacement for fetal bovine serum in mesenchymal stromal cell cultures // Transfus Med Hemother. 2013. Vol. 40, No. 5. P. 326–335. DOI: 10.1159/000354061Anitua E, Sanchez M, Merayo-Lloves J, et al. Plasma rich in growth factors (PRGF-Endoret) stimulates proliferation and migration of primary keratocytes and conjunctival fibroblasts and inhibits and reverts TGF induced myodifferentiation. Investigative ophthalmology visual science. 2011;52(9):6066–6073. DOI: 10.1167/iovs.11-7302Anitua E., Sanchez M., Merayo-Lloves J., et al. Plasma rich in growth factors (PRGF-Endoret) stimulates proliferation and migration of primary keratocytes and conjunctival fibroblasts and inhibits and reverts TGF induced myodifferentiation // Investigative ophthalmology visual science. 2011. Vol. 52, No. 9. P. 6066–6073. DOI: 10.1167/iovs.11–7302Abu-Ameerh MA, Jafar HD, Hasan MH, et al. Platelet lysate promotes re-epithelialization of persistent epithelial defects a pilot study. Int Ophthalmology. 2019;39(7):1483–1490. DOI: 10.1007/s10792-018-0968-1Abu-Ameerh M.A., Jafar H.D., Hasan M.H., et al. Platelet lysate promotes re-epithelialization of persistent epithelial defects a pilot study // Int Ophthalmology. 2019. Vol. 39, No. 7. P. 1483–1490. DOI: 10.1007/s10792-018-0968-1Santos S, Sigurjonsson ÓE, Custódio CA, Mano J. Blood Plasma Derivatives for Tissue Engineering and Regenerative Medicine Therapies. Tissue Eng Part B Rev. 2018;24(6):454–462. DOI: 10.1089/ten.TEB.2018.0008Santos S., Sigurjonsson Ó.E., Custódio C.A., Mano J. Blood Plasma Derivatives for Tissue Engineering and Regenerative Medicine Therapies // Tissue Eng Part B Rev. 2018. Vol. 24, No. 6. P. 454–462. DOI: 10.1089/ten.TEB.2018.0008Amable PR, Carias RB, Teixeira MV, et al. Platelet-rich plasma preparation for regenerative medicine: optimization and quantification of cytokines and growth factors. Stem Cell Res Ther. 2013;4(3):67. DOI: 10.1186/scrt218Amable P.R., Carias R.B., Teixeira M.V., et al. Platelet-rich plasma preparation for regenerative medicine: optimization and quantification of cytokines and growth factors // Stem Cell Res Ther. 2013. Vol. 4, No. 3. P. 67. DOI: 10.1186/scrt218Drago L, Bortolin M, Vassena C, et al. Antimicrobial activity of pure platelet-rich plasma against microorganisms isolated from oral cavity. BMC Microbiol. 2013;13:47. DOI: 10.1186/1471-2180-13-47Drago L., Bortolin M., Vassena C., et al. Antimicrobial activity of pure platelet-rich plasma against microorganisms isolated from oral cavity // BMC microbiol. 2013. Vol. 13. P. 47. DOI: 10.1186/1471-2180-13-47Del Fabbro M, Ceresoli V, Lolato A, Taschieri S. Effect of platelet concentrate on quality of life after periradicular surgery: a randomized clinical study. J Endod. 2012;38(6):733–739. DOI: 10.1016/j.joen.2012.02.022Del Fabbro M., Ceresoli V., Lolato A., Taschieri S. Effect of platelet concentrate on quality of life after periradicular surgery: a randomized clinical study // J Endod. 2012. Vol. 38, No. 6. P. 733–739. DOI: 10.1016/j.joen.2012.02.022van Osch GJ, Bernsen MR, van Buul GM, et al. Platelet-rich plasma releasate inhibits inflammatory processes in osteoarthritic chondrocytes. Am J Sports Med. 2011;39(11):2362–2370. DOI: 10.1177/036354651141927van Osch G.J., Bernsen M.R., van Buul G.M., et al. Platelet-rich plasma releasate inhibits inflammatory processes in osteoarthritic chondrocytes // Am J Sports Med. 2011. Vol. 39, No. 11. P. 2362–2370. DOI: 10.1177/036354651141927Mazzocca AD, McCarthy BR, Intravia J, et al. An in vitro evaluation of the anti-inflammatory effects of platelet-rich plasma, ketorolac, and methylprednisolone. Arthroscopy. 2013;29(4):675–683. DOI: 10.1016/j.arthro.2012.12.005Mazzocca A.D., McCarthy B.R., Intravia J., et al. An in vitro evaluation of the anti-inflammatory effects of platelet-rich plasma, ketorolac, and methylprednisolone // Arthroscopy. 2013. Vol. 29, No. 4. P. 675–683. DOI: 10.1016/j.arthro.2012.12.005Peerbooms JC, Sluimer J, Bruijn DJ, Gosens T. Positive effect of an autologous platelet concentrate in lateral epicondylitis in a double-blind randomized controlled trial: Platelet-rich plasma versus corticosteroid injection with a 1-year follow-up. Am J Sports Med. 2010;38(2):255–262. DOI: 10.1177/0363546509355445Peerbooms J.C., Sluimer J., Bruijn D.J., Gosens T. Positive effect of an autologous platelet concentrate in lateral epicondylitis in a double-blind randomized controlled trial: Platelet-rich plasma versus corticosteroid injection with a 1-year follow-up // Am J Sports Med. 2010. Vol. 38, No. 2. P. 255–262. DOI: 10.1177/0363546509355445Deikalo VP, Mastykov AN, Boloboshko KB. Obogashhennaja trombocitami plazma v lechenii zabolevanij i povrezhdenij oporno-dvigatel’nogo apparata. Vestnik VGMU. 2011;10(4):6–12. (In Russ.)Деикало В.П., Мастыков А.Н., Болобошко К.Б. Обогащенная тромбоцитами плазма в лечении заболеваний и повреждений опорно-двигательного аппарата // Вестник ВГМУ. 2011. Т. 10, No 4. С. 6–12.Marx RE. Platelet-rich plasma: evidence to support its use. J Oral Maxillofac Surg. 2004;62(4):489–496. DOI: 10.1016/j.joms.2003.12.003Marx R.E. Platelet-rich plasma: evidence to support its use // J Oral Maxillofac Surg. 2004. Vol. 62, No. 4. P. 489–496. DOI: 10.1016/j.joms.2003.12.003Huang CJ, Sun YC, Christopher K, et al. Comparison of corneal epitheliotrophic capacities among human platelet lysates and other blood derivatives. PloS one. 2018;12(2): e0171008. DOI: 10.1371/journal.pone.0171008Huang C.J., Sun Y.C., Christopher K., et al. Comparison of corneal epitheliotrophic capacities among human platelet lysates and other blood derivatives // PloS Оne. 2018. Vol. 12, No. 2. P. e0171008. DOI: 10.1371/journal.pone.0171008McCulley JP, Horowitz B, Husseini ZM, Horowitz M. Topical fibronectin therapy of persistent corneal epithelial defects. Fibronectin Study Group. Trans Am Ophthalmol Soc. 1993;91:367–386.McCulley J.P., Horowitz B., Husseini Z.M., Horowitz M. Topical fibronectin therapy of persistent corneal epithelial defects. Fibronectin Study Group // Trans Am Ophthalmol Soc. 1993. Vol. 91. P. 367–386Fu Y, Liu J, Tseng SC. Ocular surface deficits contributing to persistent epithelial defect after penetrating keratoplasty. Cornea. 2012;31(7):723–729. DOI: 10.1097/ICO.0b013e31821142eeFu Y., Liu J., Tseng S.C. Ocular surface deficits contributing to persistent epithelial defect after penetrating keratoplasty // Cornea. 2012. Vol. 31, No. 7. P. 723–729. DOI: 10.1097/ICO.0b013e31821142eeLoshkareva AO. Terapija hronicheskih narushenij jepitelizacii rogovicy gerpesvirusnoj jetiologii s ispol’zovaniem autologichnoj bogatoj trombocitami plazmy [dissertation]. Moscow; 2018. (In Russ.) Available from: https://www.dissercat.com/content/terapiya-khronicheskikh-narushenii-epitelizatsii-rogovitsy-gerpesvirusnoi-etiologii-s-ispolzЛошкарева А.О. Терапия хронических нарушений эпителизации роговицы герпесвирусной этиологии с использованием аутологичной богатой тромбоцитами плазмы: дис. … канд. мед. наук. М., 2018. Режим доступа: https://www.dissercat.com/content/terapiya-khronicheskikh-narushenii-epitelizatsii-rogovitsy-gerpesvirusnoi-etiologii-s-ispolz. Дата обращения: 02.07.2021.Borovkova NV, Filatova IA, Chentsova EV, et al. Efficacy of platelet-rich plasma lysate in patients with corneal erosion or post-traumatic scarring of the tissues of the eyelids. Russian Ophthalmological Journal. 2020;13(3):8–14. (In Russ.) DOI: 10.21516/2072-0076-2020-13-3-8-14.Боровкова Н.В., Филатова И.А., Ченцова Е.В., и др. Эффективность применения лизата богатой тромбоцитами плазмы (БоТП) у пациентов с эрозией роговицы или посттравматическим рубцеванием тканей век // Российский офтальмологический журнал. 2020. Т. 13, № 3. С. 8–14. DOI: 10.21516/2072-0076-2020-13-3-8-14Rumelt S, Bersudsky V, Blum-Hareuveni T, Rehany U. Preexisting and postoperative glaucoma in repeated corneal transplantation. Cornea. 2002;21(8):759–765. DOI: 10.1097/00003226-200211000-00005Rumelt S., Bersudsky V., Blum-Hareuveni T., Rehany U. Preexisting and postoperative glaucoma in repeated corneal transplantation. Cornea. 2002. Vol. 21, No. 8. P. 759–765. DOI: 10.1097/00003226-200211000-00005Rumelt S, Bersudsky V, Blum-Hareuveni T, et al. Preexisting and postoperative glaucoma in repeated corneal transplantation. Cornea. 2002;21(8):759–765. DOI: 10.1097/00003226-200211000-00005Rumelt S., Bersudsky V., Blum-Hareuveni T., et al. Preexisting and postoperative glaucoma in repeated corneal transplantation // Cornea. 2002. Vol. 21. No. 8. P. 759–765. DOI: 10.1097/00003226-200211000-00005Puchkovskaja NA. Lechebnaja keratoplastika i vozmozhnosti stimuljacii regenerativnoj sposobnosti rogovoj obolochki. Oftal’mologichcheskij zhurnal. 1983;2:69–71. (In Russ.)Пучковская, Н.А. Лечебная кератопластика и возможности стимуляции регенеративной способности роговой оболочки // Офтальмологический журнал. 1983. № 2. С. 69–71.Katzman LR, Jeng BH. Management strategies for persistent epithelial defects of the cornea. Saudi J Ophthalmol. 2014;28(3): 168–172. DOI: 10.1016/j.sjopt.2014.06.011Katzman L.R., Jeng B.H. Management strategies for persistent epithelial defects of the cornea // Saudi J Ophthalmol. 2014. Vol. 28, No. 3. P. 168–172. DOI: 10.1016/j.sjopt.2014.06.011Hos D, Matthaei M, Bock F, et al. Immune reactions after modern lamellar (DALK, DSAEK, DMEK) versus conventional penetrating corneal transplantation. Prog Retin Eye Res. 2019;73:100768. DOI: 10.1016/j.preteyeres.2019.07.001Hos D., Matthaei M., Bock F., et al. Immune reactions after modern lamellar (DALK, DSAEK, DMEK) versus conventional penetrating corneal transplantation // Prog Retin Eye Res. 2019. Vol. 73. P. 100768. DOI: 10.1016/j.preteyeres.2019.07.001Trufanov SV, Subbot AM, Malozhen SA, et al. Risk factors, clinical presentations, prevention, and treatment of corneal graft rejection. Vestnik oftal’mologii. 2016;132(6):108–116. (In Russ.) DOI: 10.17116/oftalma20161326108-116Труфанов С.В., Суббот А.М., Маложен С.А., и др. Факторы риска, клинические проявления, методы профилактики и лечения реакции отторжения трансплантата роговицы // Вестник офтальмологии. 2016. Т. 132, № 6. С. 108–116. DOI: 10.17116/oftalma20161326108-116